Description
GLEOSTINE (lomustine) is prescribed to treat certain types of cancers. It is a chemotherapy agent, and should only be used under the close supervision of a physician.
GLEOSTINE can be prescribed for the following types of cancers:
- Brain tumors; primary and metastatic tumors.
- Hodgkin's lymphoma, following disease progression with initial chemotherapy.
GLEOSTINE attaches to DNA and RNA, preventing the replication of cancerous cells. GLEOSTINE also attaches to specific proteins, making them inactive.
Directions
The normal dose of GLEOSTINE is 130 mg per meter-squared, rounded to the nearest 5 mg.
GLEOSTINE is available in the following capsule sizes:
One single dose of GLEOSTINE is administered every six weeks.
Ingredients
The active ingredient in GLEOSTINE is lomustine.
Fact Table |
Formula |
C9H16ClN3O2 |
License |
- |
Bioavailability |
100% |
Legal status |
RX Only |
Chemical Name |
Lomustine |
Elimination half-life |
Approximately 94 minutes, Metabolites have a serum half-life of 16 to 48 hours |
Dosage (Strength) |
10mg (20 tablets), 40mg (20 tablets) |
Pregnancy |
Consult a doctor |
Brands |
Ceenu, Gleostine |
Protein binding |
50% |
PubChem CID |
3950 |
MedlinePlus |
a682207 |
ChEBI |
6520 |
ATC code |
L01AD02 |
DrugBank |
DB01206 |
KEGG |
D00363 |
Routes of administration |
By mouth (tablets) |
Interactions
Speak with your healthcare provider if you are taking any of the following:
- Baracitinib
- BCG (Bacillus Calmette-Guerin)
- Chloramphenicol
- Cladribine
- Clozapine
- Coccidiodes immitis Skin Test
- Deferiprone
- Denosumab
- Dipyrone
- Echinacea
- Fingolimod
- Inebilizumab
- Leflunomide
- Lenograstim
- Lipegfilgrastim
- Mesalamine
- Natalizumab
- Nivolumab
- Ocrelizumab
- Ozanimod
- Palifermin
- Pidotimod
- Pimecrolimus
- Promazine
- Roflumilast
- Siponimod
- Sipuleucel-T
- Tacrolimus
- Tertomotide
- Tofacitinib
- Trastuzumab
- Upadacitinib
- Vaccines
Cautions
An overdose of GLEOSTINE can be fatal. Take GLEOSTINE exactly as directly once every six weeks.
GLEOSTINE can cause myelosuppression (bone marrow suppression), which is a decrease in the activity of bone marrow cells. Complete blood counts need to be monitored regularly while taking GLEOSTINE.
GLEOSTINE should not be used by women who are pregnant or breastfeeding.
GLEOSTINE can cause lung toxicity. Lung function should be monitored while taking this medication.
Long-term use can cause secondary malignancies.
Monitor liver function and kidney function while taking GLEOSTINE.
Side Effects
Common adverse reactions to GLEOSTINE may include:
- Alopecia
- Ataxia
- Blindness
- Disorientation
- Dysarthria
- Lethargy
- Nausea
- Optic atrophy
- Stomatitis
- Visual disturbances
- Vomiting
References
Gleostine [package insert].Miami, FL: NextSource Biotechnology; 2016.
About Dr. Conor Sheehy (Page Author)
Dr. Sheehy (BSc Molecular Biology, PharmD) works a clinical pharmacist specializing in cardiology, oncology, and ambulatory care. He’s a board-certified pharmacotherapy specialist (BCPS), and his experience working one-on-one with patients to fine tune their medication and therapy plans for optimal results makes him a valuable subject matter expert for our pharmacy. Read More....
IMPORTANT NOTE:
The above information is intended to increase awareness of health information and does not suggest treatment or diagnosis. This information is not a substitute for individual medical attention and should not be construed to indicate that use of the drug is safe, appropriate, or effective for you. See your health care professional for medical advice and treatment.
Product Code : 13265